# US 2024/0016799 A1 · Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0016799 A1
- Document ID: US20240016799A1
- Status: Published application
- Kind: A1
- Application number: 18/355,811
- Filed: 2023-07-20
- Published: 2024-01-18
- Earliest claimed: 2017-09-28
- Assignees: Medicon Pharmaceuticals, Inc.
- Applicants: Medicon Pharmaceuticals, Inc.
- Inventors: Basil RIGAS
- Web page: https://patentgrep.com/patent/US20240016799A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- C07F 9/2458: {of aliphatic amines}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/664: Amides of phosphorus acids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- C07C 233/78: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C 323/62: having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 295/185: from aliphatic carboxylic acids
- C07F 9/222: {Amides of phosphoric acids}
- C07C 317/44: having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07F 9/650952: {having the nitrogen atoms in the positions 1 and 4}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and methods of use thereof are also described.

## Claims

### Claim at position 1

-22. (canceled)

### Claim 23

A method of treating a disease or disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound selected from compound 1, compound 2, compound 3, compound 4, compound 5, and compound 6, or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof:

### Claim 24 (depends on 23)

The method of claim 23, wherein the compound, or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, is included in a pharmaceutical composition further comprising a pharmaceutically acceptable excipient.

### Claim 25 (depends on 23)

The method of claim 23, wherein the disease or disorder is an inflammation disease or disorder, a cancer, a neurodegenerative diseases or disorder, a cardiovascular disease or disorder, an ocular disease or disorder, or an angiogenic disease or disorder.

### Claim 26 (depends on 25)

The method of claim 25, wherein the cancer is ovarian cancer, colon cancer, leukemia, gastric cancer, lung cancer, pancreatic cancer, or a cancer characterized by one or more K-Ras mutations.

### Claim 27 (depends on 25)

The method of claim 25, wherein the cancer is chemoresistant to other therapeutic agents.

### Claim 28 (depends on 23)

The method of claim 23, wherein the treatment includes inhibiting VEGF expression.

### Claim 29 (depends on 23)

The method of claim 23, wherein the disease or disorder is an ocular disease or disorder.

### Claim 30 (depends on 23)

The method of claim 23, wherein the disease or disorder is diabetic retinopathy.

### Claim 31 (depends on 23)

The method of claim 23, wherein the disease or disorder is dry eye disease.

### Claim 32 (depends on 23)

The method of claim 23, wherein the disease or disorder is a retinopathy selected from diabetic retinopathy, retinopathy of prematurity, VEGF retinopathy, age related macular degeneration, retinal vein occlusion, and hypertensive retinopathy.

### Claim 33 (depends on 23)

The method of claim 23, further comprising the step of administering a therapeutically effective amount of an additional active agent.

### Claim 34 (depends on 33)

The method of claim 33, wherein the additional active agent is selected from the group consisting of an antibiotic, cyclosporine, lifitegrast, and a combination thereof.

### Claim 35 (depends on 23)

The method of claim 23, wherein the compound is administered topically to the patient.

### Claim 36 (depends on 35)

The method of claim 35, wherein the compound is administered topically to the patient in an eye drop dosage form.

### Claim 37 (depends on 23)

The method of claim 23, wherein the compound is administered by intraocular injection.

### Claim 38

A compound selected from compound 5 and compound 6, or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof:

### Claim 39 (depends on 38)

A pharmaceutical composition comprising a compound of claim 38, or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, and a pharmaceutically acceptable excipient.
